MYX mayne pharma group limited

Help me understand Mr Chairman, page-4

  1. 1,464 Posts.
    lightbulb Created with Sketch. 289
    Mayne CEO O'Brien , sees the transaction as a validation of the company's growth strategy . " Attracting an offer from a strategic buyer who is active in the US dermatology and women's health markets such as Cosette , reflects the excellent work our teams have been doing ." he said . "Having broadened our portfolio and improved patient access through a refined U.S. channel strategy , we have executed against our corporate against our corporate strategies with precision ." This tells us our new CEO / Board never working in our interest . Method in their madness alright doing some of the seemingly nonsensical decisions mad which helped drive share value down and making sure they stayed down by consolidating them to the extent they did .
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.08
Change
-0.120(2.31%)
Mkt cap ! $412.7M
Open High Low Value Volume
$5.19 $5.19 $4.97 $918.5K 181.9K

Buyers (Bids)

No. Vol. Price($)
1 1200 $5.05
 

Sellers (Offers)

Price($) Vol. No.
$5.08 6898 1
View Market Depth
Last trade - 16.10pm 16/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.